Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of IMM2902 in HER2-expressing Advanced Solid Tumors
CTR20212375Phase 2Terminated
- Sponsor
- ImmuneOnco
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMM2902 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), gastric cancer (GC) and 5 more, sponsored by ImmuneOnco. Started Sep 2021; status: terminated.
02
Drugs
IMM2902
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)gastric cancer (GC)biliary cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20212375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212375.